Added, Removed or Changed. Date of Change. No Change

Similar documents
CENTENE PHARMACY & THERAPEUTICS COMMITTEE THIRD QUARTER 2017 NEW DRUG ARRIVALS SUMMARY TABLE. Utilization Management Recommendation

Well Informed. Utilization Program Updates to Promote Guideline Adherence. Effective January 1, 2018:

Added, Removed or Changed. Added, Removed or Changed

Clinical Overview of Innovative New Drug Approvals in 2017

Medicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5

Oral Oncology Agents. August 2017 Update. SGLT-2 Category Update. Removal of Medical Foods

New Drugs of ,3,5,7,10,14,16,20,22,24,26,28,30,32,34,36,38,40,41,43,45-86 Brand Name/ Generic Name/ Approved Indication

LUNCH AND LEARN. May 11, CE Activity Information & Accreditation

Brineura (cerliponase alfa) NEW PRODUCT SLIDESHOW

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

An Analysis of Exchange Plan Benefits for Certain Medicines

BRINEURA (cerliponase alfa)

Formulary. Update. At A Glance. Formulary Additions ISSUE 4 VOLUME 11 AUGUST 2017

Advanced Control Formulary Change Summary Report Effective

New Drug Update th Annual Oklahoma Academy of Physician Assistants CME Conference September 22, 2017

Xenazine. Xenazine (tetrabenazine) Description

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications

Quarterly pharmacy formulary change notice

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017

Quarterly pharmacy formulary change notice

PEI Drug Programs. Issue February 20, 2009

Quarterly pharmacy formulary change notice

Washington October Newsletter

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)

TO: Maine Drug Utilization Review Board DATE: 6/29/2017 RE: Maine DUR Board Meeting minutes from June 27, 2017

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Cover story. Austedo Ingrezza Brineura Alunbrig Rydapt Tymlos Imfinzi Radicava Kevzara Baxdela Bevyxxa

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

New Product to Market: Lucemyra Magellan Health, Inc. All rights reserved.

Austedo. Austedo (deutetrabenazine) Description

Regulatory Status FDA-approved indication: Otrexup and Rasuvo are folate analog metabolic inhibitors indicated for: (1-2)

Xultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow

New Drug Update: 2018

Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:

Pharmacology. An Introduction. Henry Hitner, Ph.D. Barbara Nagle, Ph.D. Learn. Neuroscience, Physiology,

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?

Reason for change. Recently approved. Recently approved. Recently approved. Recently approved. Recently updated. Recently approved.

Contents The following Hemophilia treatment products are being added to the medical policy:

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES

February - March - April 2017 Selected Content Updates. Approved to treat chorea associated with Huntington disease

Xenazine. Xenazine (tetrabenazine) Description

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February

XADAGO (safinamide) oral tablet

Well Informed. A Comprehensive Approach to Pain Management. Pain Guardian

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150

Developing a Oncology Treatment Resource for Claims-Based Research: Innovation with Medications

FDA Approval LIST. WellINFORMED

Manufacturing and Marketing permission issued from SND Division from to

Drug Formulary Update, January 2013

Quarterly pharmacy formulary change notice

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.

Specialty Pharmacy Pipeline

Drugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC

Vesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza )

2018 Formulary Update

Ingrezza. Ingrezza (valbenazine) Description

Oregon Health Plan prescription benefit updates

XATMEP (methotrexate) oral solution

ANNEX - List of the paediatric MAs/variations in 2014 i

CANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE

Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals

Endocrine system pathology

continuing education for pharmacists

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

Pharmacy and Therapeutics Committee

Xolair. Xolair (omalizumab) Description

Step Therapy Approval Criteria

Stelara. Stelara (ustekinumab) Description

Covered California Formulary Analysis of Top 100 Drugs and Select Classes Prepared for the California HealthCare Foundation Avalere.

Xolair. Xolair (omalizumab) Description

Lynparza. Lynparza (olaparib) Description

Nclex para la Enfermera Hispana

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Pharmacy and Medical Guideline Updates

Nucala. Nucala (mepolizumab) Description

1.5 PHARMACOLOGY CREDITS

FDA Approval LIST. WellINFORMED. Generic Name(s) Brand Name (manufacturer) Therapeutic Use. Brief Description. Potential Impact.

Rayos Prior Authorization Program Summary

Migraine 2/6/2019. New Medications in Neurology. Learning Objectives. Disclosure. Learning Objectives. Midwinter Meeting February 9, 2019

Midwinter Meeting February 9, 2019

Upper Peninsula Health Plan Advantage (HMO) (List of Covered Drugs)

Pharmacy Management Drug Policy

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Quarterly pharmacy formulary change

Soliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow

RITUXAN (rituximab and hyaluronidase human)

Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals

ACTEMRA (tocilizumab)

Kymriah. Kymriah (tisagenlecleucel) Description

Title Cancer Drug Phase Status

Learning Objectives. ! Students will become familiar with the 3 treatment solutions for osteoporosis. ! Students should be able to define osteoporosis

NB Drug Plans Formulary Update

Transcription:

One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your care. Because the formulary is reviewed on an ongoing basis, we want to keep you informed of coming and recent changes to our covered drug lists. The following is a list of changes that have occurred. The online pharmacy tools and resources are updated with these decisions by the effective date of the change. This list applies to members of Plans and Health Plans. This list does not apply to Federal Employee Program members or Medicare Advantage members. TABLE A. TABLED MEDICATIONS: Plan Class/Category Tier = Benefit Level for Drug Under The Tirosint Solution (Levothyroxine) Thyroid Product Used for Hypothyroidism and Pituitary thyrotropinstimulating hormone (TSH) suppression N/A No Tabled until the product hits the market Tabled until the product hits the market Tabled until the product hits the market Soliqua (insulin glargine & lixisenatide) Antidiabetic Agent Used to help control Type 2 Diabetes Mellitus in individuals who are inadequately controlled on basal insulin No Not Covered MN-PA MN-PA Xultophy (insulin degludec & liraglutide) Antidiabetic Agent Used to help control Type 2 Diabetes Mellitus in individuals who are inadequately controlled on basal insulin Added Tier 3 with PA Tier 2 with PA Tier 2 with PA Zejula (niraparib) Antineoplastic Agent Maintenance treatment of Ovarian, fallopian tube or primary peritoneal cancer Added Tier 5 with PA Tier 2 with PA Tier 4 with PA 2017 by Blue Cross of Idaho, an independent licensee of the Blue Cross and Blue Shield Association

TABLE B. NEWLY REVIEWED MEDICATIONS: Plan Xadago (safinamide) Austedo (deutetrabenazine) Class/Category Anti-Parkinson Agent, MAO Type B Inhibitor Adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing off episodes. Central Monoamine- Depleting Agent, Vesicular Monoamine Transporter 2 Inhibitor Treatment of chorea associated with Huntington disease Tier = Benefit Level for Drug Under The No Not Covered Not Covered Not Covered Ingrezza (valbenazine) Central Monoamine- Depleting Agent, Vesicular Monoamine Transporter 2 Inhibitor Treatment of adults with tardive dyskinesia No Tabled Tabled Tabled Siliq (brodalumab) Anti-interleukin 17- Receptor Antibody Treatment of plaque psoriasis Added for No change for QHP Not Covered Tier 3 with PA Tier 4 with PA Kevzara (sarilumab) Antirheumatic, Disease Modifying, Interleukin-6 Receptor Antagonist Treatment of Rheumatoid Arthritis Tymlos (abaloparatide) Parathyroid Hormone Analog Treatment of Osteoporosis Added Tier 5 with PA Tier 2 with PA Tier 3 with PA

Plan Intrarosa (prasterone) Alunbrig (brigatinib) Rydapt (midostaurin) Brineura (cerliponase alfa) Ocrevus (ocrelizumab) Radicava (edaravone) Imfinzi (durvalumab) Synthetic Steroid Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause Anaplastic Lymphoma Kinase Inhibitor, Tyrosine Kinase Inhibitor Treatment of non-small cell lung cancer, metastatic FLT3 Inhibitor, Tyrosine Kinase Inhibitor Treatment of Acute Myeloid Leukemia, FLT3- Postive. Treatment of Mast cell Leukemia Hydrolytic Lysosomal N- Terminal Tripeptidyl Peptidase Used to delay the loss of ambulation in symptomatic pediatric patients 3 years and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) Anti-CD20 Monoclonal antibody Treatment of relapsing or primary progressive forms of Multiple Sclerosis Free Radical Scavenger Treatment of Amyotrophic lateral sclerosis (ALS) Anti-PD-L1 Monoclonal Antibody Treatment of Urothelial carcinoma, locally advanced or metastatic Added for No for QHP Not Covered Tier 3 with PA Tier 3 with PA

TABLE C. PREVIOUSLY REVIEWED/LINE EXTENSIONS: Plan Class Tier = Benefit Level for Drug Under The Airduo RespiClick (fluticasone + salmeterol inhalation powder) Fluticasone + Salmeterol Inhalation Powder Corticosteroid, Inhalant (Oral), Beta2 Agonist, Beta2-Adrenergic Agonist Treatment of asthma in patients 12 years and older Corticosteroid, Inhalant (Oral), Beta2 Agonist, Beta2-Adrenergic Agonist Treatment of asthma in patients 12 years and older Corticosteroid, Inhalant (Oral) ArmonAir RespiClick Maintenance treatment of (fluticasone inhalation asthma as prophylactic powder) therapy in patients 12 years and older Ergocal (ergocalciferol 2500u capsule) Vitamin D Analog Used as dietary supplement. Treatment of familial hypophosphatemia, rickets, and Hypoparathyroidism No Not Covered MN-PA MN-PA Added Tier 2 Tier 1 Tier 1 No Not Covered MN-PA MN-PA No Not Covered Not Covered Not Covered Jadenu Sprinkle (deferasirox oral granules) Chelating Agent Treatment for chronic iron overload due to transfusions. Treatment of chronic iron overload in non-transfusion-dependent thalassemia syndromes Morphabond (morphine sulfate ER tablets) Analgesic, Opioid Management of severe pain requiring daily, around-the-clock, long-term opioid treatment Added for No for QHP Not Covered Tier 3 with PA Tier 3 with PA Mydayis (amphetaminedetroamphetamine ER capsules) Central Nervous System Stimulant Treatment of ADHD No Not Covered MN-PA MN-PA

Plan Rituxan Hycela (rituximab/hyaluronida se SC injection) Monoclonal Antibody Treatment of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Chronic Lymphocytic Leukemia Selzentry (maraviroc oral solution) Antiretroviral, CCR5 Antagonist Treatment of HIV-1 infection Added Tier 3 Tier 2 Tier 2 Xatmep (methotrexate 2.5mg/ml) Syndros (dronabinol oral solution) Antirheumatic, Disease Modifying Treatment of pediatric patients with acute lymphoblastic leukemia. Management/Treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis. Antiemetic, Appetite Stimulant Treatment of anorexia associated with weight loss in patients with AIDS. Treatment for chemotherapy-induced nausea and vomiting No Not Covered MN-PA MN-PA Added Tier 4 with QL Tier 3 with QL Tier 3 with QL Haegarda (C1 esterase inhibitor (Human)) C1 Esterase Inhibitor Routine prophylaxis against angioedema attacks in adults and adolescents with HAE Selenium Sulfide (selenium sulfide lotion 2.25%) Antiseborrheic Agent, Topical Treatment of dandruff, scalp seborrhea and treatment of tinea versicolor No Not Covered Not Covered Not Covered Rayaldee (calcifediol ER capsules) Vitamin D Analog Treatment of secondary hyperparathyroidism No Not Covered Not Covered Not Covered

TABLE D. THERAPEUTIC CLASS REVIEW: Plan Class Tier = Benefit Level for Drug Under The No s